In its latest draft guidance, NICE has recommended trastuzumab (Herceptin, Roche Products) for certain patients with metastatic gastric cancer who have high levels of human epidermal growth factor receptor 2 (HER2). HER2 is a protein found on the surface of some cancer cells. Gastric cancer cells have higher levels of the HER2 protein than normal cells. Trastuzumab attaches itself to the protein so that epidermal growth factor production is reduced in the cancer cells; this stops the cells from dividing and growing...
More...
More...